Transhepatic stent placement for portal vein obstruction after hepatobiliary and pancreatic surgery: long-term efficacy and risk factor for stent failure

2020 ◽  
Author(s):  
Jae Hwan Lee ◽  
Chang Jin Yoon ◽  
Won Seok Choi
Keyword(s):  
Risk Factor ◽  
Portal Vein ◽  
Stent Placement ◽  
Pancreatic Surgery ◽  
Term Efficacy ◽  
Portal Vein Obstruction ◽  
Hepatobiliary And Pancreatic Surgery

scholarly journals Portal vein stent placement after hepatobiliary and pancreatic surgery

2020 ◽  
Vol 405 (5) ◽  
pp. 657-664 ◽  
Author(s):  
Ammar Khan ◽  
Dyre Kleive ◽  
Einar Martin Aandahl ◽  
Bjarte Fosby ◽  
Pål-Dag Line ◽  
...  
Keyword(s):  
Portal Vein ◽  
Stent Placement ◽  
Pancreatic Surgery ◽  
Hepatobiliary And Pancreatic Surgery

Factors associated with 30-day readmission and long-term efficacy of enteral stent placement for malignancy

2013 ◽  
Vol 28 (4) ◽  
pp. 1194-1201 ◽  
Author(s):  
Udayakumar Navaneethan ◽  
Sudhir Duvuru ◽  
Ramprasad Jegadeesan ◽  
Preethi G. K. Venkatesh ◽  
Norma G. Gutierrez ◽  
...  
Keyword(s):  
Stent Placement ◽  
Factors Associated ◽  
Enteral Stent ◽  
Term Efficacy

Long-Term Neuropsychological Outcome in Children Undergoing Portal-Systemic Shunts for Portal Vein Obstruction Without Liver Disease

1986 ◽  
Vol 5 (6) ◽  
pp. 861-866 ◽  
Author(s):  
Daniel Alagille ◽  
Jeanne-Charlotte Carlier ◽  
Matty Chiva ◽  
Richard Ziadé ◽  
Marianne Ziadé ◽  
...  
Keyword(s):  
Liver Disease ◽  
Portal Vein ◽  
Neuropsychological Outcome ◽  
Portal Vein Obstruction

Portal Vein Stent Placement in Five Patients with Chronic Portal Vein Thrombosis Prior to Pancreatic Surgery

2016 ◽  
Vol 27 (6) ◽  
pp. 889-894 ◽  
Author(s):  
Ugo Scemama ◽  
David Jérémie Birnbaum ◽  
Mehdi Ouaissi ◽  
Olivier Turrini ◽  
Vincent Moutardier ◽  
...  
Keyword(s):  
Portal Vein ◽  
Portal Vein Thrombosis ◽  
Stent Placement ◽  
Pancreatic Surgery ◽  
Vein Thrombosis

Long-term follow-up of children with extrahepatic portal vein obstruction: impact of an endoscopic sclerotherapy program on bleeding episodes, hepatic function, hypersplenism, and mortality

2009 ◽  
Vol 44 (10) ◽  
pp. 1877-1883 ◽  
Author(s):  
João Gilberto Maksoud-Filho ◽  
Manuel Ernesto Peçanha Gonçalves ◽  
Silvia Regina Cardoso ◽  
Nelson Elias Mendes Gibelli ◽  
Uenis Tannuri
Keyword(s):  
Portal Vein ◽  
Hepatic Function ◽  
Endoscopic Sclerotherapy ◽  
Extrahepatic Portal Vein Obstruction ◽  
Portal Vein Obstruction ◽  
Long Term Follow Up ◽  
Bleeding Episodes

Efficacy of Lipid Apheresis: Definitions and Influencing Factors

1995 ◽  
Vol 18 (4) ◽  
pp. 210-215 ◽  
Author(s):  
T. Bosch ◽  
D. Seidel ◽  
H. J. Gurland
Keyword(s):  
Coronary Artery Disease ◽  
Risk Factor ◽  
Coronary Artery ◽  
Clinical Efficacy ◽  
Plasma Volume ◽  
Lipid Apheresis ◽  
Term Efficacy ◽  
Risk Factor Reduction ◽  
Artery Disease

The comparison of efficiency of currently available lipid apheresis systems has been hampered by different definitions of efficacy and poorly controlled apheresis conditions. This paper suggests definitions of efficacy and standardization of its determinants. The acute efficacy of risk factor reduction reflects the relative decrease of pathogen by a single treatment session compared to preapheresis levels. Standardization of treated plasma volume in relation to the patients plasma volume and correction of changes in plasma volume during the procedure are mandatory. Its determination is most useful in the technical evaluation of new systems. The long-term efficacy of risk factor reduction as compared to baseline is determined by mean interapheresis levels of e.g. LDL-C in the pseudo-steady-state after about 3 months of regular treatment. It is the major criterion for potential regression of coronary artery disease and absolute average plasma levels of 120 ≤ mg/dl LDL-C should be attained. It is influenced by the acute efficacy of the system, apheresis frequency and rebound kinetics. The clinical efficacy is defined by apheresis induced reduction of coronary morbidity and mortality. It is influenced by long-term risk factor reduction, the selectivity of the system as well as the control of non-lipid risk factors. Apheresis related effects on coronary artery disease comprise functional improvements of hemorheology and vasomotion as well as morphological benefits like regression of luminal narrowing and plaque stabilization. In conclusion, the acute efficacy of apheresis systems should be determined under strictly controlled conditions; however, as apheresis independent factors influence long-term efficacy and, even more so, clinical efficacy of the treatment, differences between the available systems are blurred so that factors like costs and ease of handling may eventually significantly influence the choice of procedure.

Sign in / Sign up

Export Citation Format

Share Document